Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
Dec 11, 2025, 14:08Samwel Mikaye: Overview of Deep Vein Thrombosis (DVT) and Cellulitis
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report
-
Dec 11, 2025, 12:08Laura Girardi Compares US, CT and MRI in Portal Vein Thrombosis
-
Dec 11, 2025, 11:55Dino Mehic on BDUC: What Do We Know?